Earnings Watch, Coinbase IPO, Microsoft acquisition, and Alibaba fine Earnings Watch, Coinbase IPO, Microsoft acquisition, and Alibaba fine Earnings Watch, Coinbase IPO, Microsoft acquisition, and Alibaba fine

Earnings Watch, Coinbase IPO, Microsoft acquisition, and Alibaba fine

Equities 10 minutes to read
Peter Garnry

Head of Equity Strategy

Summary:  It is a busy week ahead for equities with the Q1 earnings season starting on Wednesday with important earnings from Wells Fargo, JPMorgan Chase, and Teladoc Health. Coinbase, the largest cryptocurrency exchange, is also on going public on Wednesday through a direct listing at a rumoured valuation of $100bn which is hefty relative to other exchanges in more traditional financial instruments. Microsoft is rumoured to buy Nuance Communications in a push into health care services and acquiring key speech recognition technology. Finally, we touch on the Alibaba antirust fine of $2.8bn.

Today’s equity update will cover many different topics, but we start with the most important one being the Q1 earnings season starting this week on Wednesday with Wells Fargo and JPMorgan Chase reporting. These two US banks have an enormous footprint in both commercial and consumer banking and will thus provide great insights into the US economic rebound and credit quality. We expect financials to be the big positive surprise during the Q1 earnings season driven by stronger investment banking fees and improving fundamentals in the banking business driven by loan-loss reserves being reduced.

Teladoc Health which is part of our bubble stocks basket is also reporting on Wednesday and will be a key test of sentiment in richly valued stocks. The company grew revenue by 145% y/y in Q4 but at the expense of cash from operations going deeply negative. Analysts are expecting revenue growth of 150% y/y in Q1 with revenue reaching $2bn in 2021.

The overall key theme in Q1 will be whether technology companies will continue to outperform the rest of the market in terms of earnings growth or the positive impulse during the pandemic is finally slowing off, and potentially more rapidly than expected. As the chart below shows, Nasdaq 100 earnings are up 17.5% since Q4 2019 with MSCI World up 3.3% and S&P 500 down 5.8%.

The most important earnings this week:

  • Tuesday: Fastenal
  • Wednesday: Wells Fargo, Teladoc Health, Tesco, JPMorgan Chase, Goldman Sachs, First Republic Bank
  • Thursday: Charles Schwab, Progressive, PepsiCo, Bank of America, Citigroup, PPG Industries, UnitedHealth, BlackRock, US Bancorp, Truist Financial, Delta Air Lines
  • Friday: Tractor Supply

Coinbase IPO and the sustainability of fees

Probably one of the most anticipated IPOs within the crypto industry ever is due on Wednesday with Coinbase, the largest exchange on cryptocurrencies, going public through a direct listing on the Nasdaq exchange under the Saxo ticker code COIN:xnas. The crypto exchange recently announced Q1 net revenue figures of close to $1.8bn which is almost twice the 2020 revenue of Euronext which is one of the largest exchanges in the world in traditional financial instruments. This is really the story of massive increase in adoption of cryptocurrency trading over the past year with Coinbase active userbase hitting 56mn, but it is also a story of elevated transaction fees compared to traditional financial instruments.

It is our expectations that Coinbase will experience fee compression over time as competition heats up. Financial performance for 2021 comes with great uncertainty and the rumoured $100bn valuation of Coinbase seems quite aggressive given that the Intercontinental Exchange is valued at $66bn, so we think all investors should be patient with Coinbase and let the company report a couple of quarterly earnings first before taking big bets on the cryptocurrency exchange. We also covered the Coinbase figures from their S-1 filing in this recent crypto analysis. In combination with the Coinbase IPO we will add it to our Crypto & Blockchain theme basket which we have done, but not yet published, and then officially launch this basket late this week.

Microsoft in talks to acquire Nuance Communications

The big news in mergers & acquisitions over the weekend was that Microsoft is rumoured to be in talks to acquire the speech recognition company Nuance Communications which has a large presence in the health care sector. The acquisition is rumoured to be set at $56 per share valuing the company at around $16bn and offering existing shareholders a premium of 23% over Friday’s close. The acquisition makes sense as speech recognition technology arguably is going to be key in the future of digitalisation and robotics technology and Microsoft could leverage its commercial distribution to help Nuance to get wider adoption. It is also obvious that Microsoft has many synergies of this technology across their other businesses. Nuance’s stock price has been rallying 212% from the lows in 2020 which looks odd given the sideways pattern over the past 13 years.

Source: Saxo Group

The acquisition is also not given, and we think it could become a key test of antitrust regulation in the US. While the acquisition seems small and innocent it does catapult Microsoft into the health care sector business, and it allows Microsoft to gobble up key technology. With the increased focus on these major technology companies regulators might request Microsoft to insure that it will not limit competition.

Alibaba is fined $2.8bn in antitrust investigation

The continuing saga of Chinese technology regulation took another turn over the weekend with Alibaba being fined $2.8bn because of the recent antitrust investigation. The fine is just above 10% of the company’s free cash flow in a single year and thus does not pose a big problem longer term for Alibaba and the share price also rose in Hong Kong trading as regulators closed the investigation with the fine and said that they like Alibaba and its impact on China. Sentiment on Alibaba shares might improve over the near term, but the longer-term concern is still around the policy objective of more competition by limiting the power of Chinese technology companies over the consumer and to what degree it will impact long-term earnings growth. We have no firm estimate on the impact and we will have to update our view quarter by quarter as we see how regulation impacts the technology sector.

Source: Saxo Group

The Saxo Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments. Saxo does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo or its affiliates.

Saxo Capital Markets HK Limited
19th Floor
Shanghai Commercial Bank Tower
12 Queen’s Road Central
Hong Kong

Contact Saxo

Select region

Hong Kong S.A.R
Hong Kong S.A.R

Saxo Capital Markets HK Limited (“Saxo”) is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo holds a Type 1 Regulated Activity (Dealing in Securities); Type 2 Regulated Activity (Dealing in Futures Contract); Type 3 Regulated Activity (Leveraged Foreign Exchange Trading); Type 4 Regulated Activity (Advising on Securities) and Type 9 Regulated Activity (Asset Management) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products may result in your losses exceeding your initial deposits. Saxo does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo does not take into account an individual’s needs, objectives or financial situation. Please click here to view the relevant risk disclosure statements.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-hk/about-us/awards.

The information or the products and services referred to on this site may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and services offered on this website are not directed at, or intended for distribution to or use by, any person or entity residing in the United States and Japan. Please click here to view our full disclaimer.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc. Android is a trademark of Google Inc.